Liliya Ziganshina who is a Professor and one of the leading authors of the research took part in a study regarding the access to medicine with specialist’s advice and procedure support from the Health Action International, as well as, World Health Organization. In 2014, later on, another leading author, Chinara M. Razzakova for her Doctor of Philosophy thesis, continued this vital research.
The major foundation for the improvement of access to medicines is the availability of medicines and reliable information on the prices. This can be done by developing public policy and proof-based programs. The evaluation of medicine price alterations in the pharmaceutical industry and the components of price makes it convenient for the different countries’ governments to assess the consistency, as well as, the success of their policies of the regulation of prices and their approaches on the containment of price.
It becomes possible for the governments to compare their expenditures on health with those of other countries which have a similar level of development when there is the availability of reliable information on the prices of medicines. Up till 2002, there wasn’t any single global approach for accessing the medicines studies; the researches which were conducted at that time employed approaches which didn’t allow complete assessment or comparisons on an international level. It was challenging to compare the outcomes of the studies among themselves because of the differences in the methodologies which were applied.
In 2001, Health Action International in partnership with the World Health Organization developed a mutual project and created an all-inclusive procedure to measure the prices of the medicines, their accessibility, as well as, affordability for the comparison of results across different countries and at various time periods.
The method employed for the collection of information was the joint HAI/WHO method. Since 2009, different price containing methods have been implemented in the Russian Federation inclusive of the commanding of utmost wholesale & retail mark-ups and the registering of the max price of selling of medicines from the list of Vital Medicines.
There was a noticeable drop in prices in 2015 compared to the prices in 2011. By far 2 papers have been created and the team has planned to finalize the analysis of pricing for 2010 to 2018 and make the results available to the public